Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
You may also be interested in...
Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.